作者回复：西洛他唑、草酸萘呋胺酯和己酮可可碱治疗间歇性跛行疗效的系统评价（《英国外科杂志》2012年；99: 1630 - 1638） - Suppr

Suppr

超能文献

Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).

作者信息

Stevens J W, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G

机构信息

Centre for Bayesian Statistics in Health Economics, University of Sheffield, Regent Court, Sheffield, S1 4DA, UK.

出版信息

Br J Surg. 2013 Dec;100(13):1838-9. doi: 10.1002/bjs.9358.

DOI:10.1002/bjs.9358

PMID:24227373

Abstract

摘要

相似文献

Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).

Br J Surg. 2013 Dec;100(13):1838-9. doi: 10.1002/bjs.9358.

Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).

Br J Surg. 2013 Dec;100(13):1838. doi: 10.1002/bjs.9357.

Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.

Br J Surg. 2012 Dec;99(12):1630-8. doi: 10.1002/bjs.8895. Epub 2012 Oct 3.

Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.

Angiology. 2014 Mar;65(3):190-7. doi: 10.1177/0003319712474335. Epub 2013 Jan 31.

Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.

Curr Med Res Opin. 2005 Jun;21(6):817-26. doi: 10.1185/030079905X41471.

A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.

Health Technol Assess. 2011 Dec;15(40):1-210. doi: 10.3310/hta15400.

The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.

Clin Ther. 2014 Aug 1;36(8):1290-301. doi: 10.1016/j.clinthera.2014.06.010. Epub 2014 Jul 8.

[The antagonist of type-II serotonin receptors naftidrofuryl in the treatment of patients with intermittent claudication].

Ter Arkh. 1996;68(2):49-53.

Comparative effects of cilostazol and other therapies for intermittent claudication.

Am J Cardiol. 2001 Jun 28;87(12A):19D-27D. doi: 10.1016/s0002-9149(01)01673-3.

Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication?

J Fam Pract. 2001 Feb;50(2):181.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).

作者信息

Stevens J W, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G

机构信息

Centre for Bayesian Statistics in Health Economics, University of Sheffield, Regent Court, Sheffield, S1 4DA, UK.

出版信息

Br J Surg. 2013 Dec;100(13):1838-9. doi: 10.1002/bjs.9358.

DOI:10.1002/bjs.9358

PMID:24227373

Abstract

摘要